|
Market Closed -
Nasdaq
04:00:00 15/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 505.75 USD | -2.07% |
|
+4.49% | +11.56% |
| 08-12 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 08-11 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,834 | 74,127 | 104,849 | 103,707 | 115,026 | 130,897 | - | - |
| Change | - | 32.76% | 41.44% | -1.09% | 10.91% | 13.8% | - | - |
| Enterprise Value (EV) 1 | 48,309 | 63,349 | 93,630 | 97,591 | 108,418 | 116,656 | 112,460 | 106,499 |
| Change | - | 31.13% | 47.8% | 4.23% | 11.09% | 7.6% | -3.6% | -5.3% |
| P/E | 24.4x | 22.5x | 29.3x | -194x | 29.6x | 29.8x | 24.5x | 20.3x |
| PBR | 5.53x | 5.33x | 5.96x | 6.4x | 6.17x | 5.59x | 4.65x | 3.84x |
| PEG | - | 0.5x | 3.51x | 2x | -0x | 2.8x | 1.1x | 1x |
| Capitalization / Revenue | 7.37x | 8.3x | 10.6x | 9.41x | 9.58x | 9.92x | 8.98x | 8x |
| EV / Revenue | 6.38x | 7.09x | 9.49x | 8.86x | 9.03x | 8.85x | 7.71x | 6.51x |
| EV / EBITDA | 10.8x | 12.8x | 20.6x | 108x | 19.8x | 20x | 16.7x | 13.7x |
| EV / EBIT | 11.1x | 13.2x | 21.4x | 140x | 20.6x | 20.8x | 17.3x | 13.8x |
| EV / FCF | 20.1x | 16.1x | 28.1x | -123x | 33.9x | 23.1x | 19.9x | 14.3x |
| FCF Yield | 4.99% | 6.2% | 3.56% | -0.81% | 2.95% | 4.33% | 5.01% | 7.01% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 16.98 | 20.64 | 24.93 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 13,189 | 14,584 | 16,361 |
| EBITDA 1 | 4,470 | 4,941 | 4,556 | 902.8 | 5,473 | 5,831 | 6,737 | 7,772 |
| EBIT 1 | 4,344 | 4,793 | 4,375 | 695.6 | 5,263 | 5,599 | 6,510 | 7,699 |
| Net income 1 | 2,342 | 3,322 | 3,620 | -535.6 | 3,953 | 4,316 | 5,214 | 6,381 |
| Net Debt 1 | -7,525 | -10,778 | -11,218 | -6,116 | -6,608 | -14,241 | -18,437 | -24,399 |
| Reference price 2 | 219.60 | 288.78 | 406.89 | 402.70 | 453.36 | 505.75 | 505.75 | 505.75 |
| Nbr of stocks (in thousands) | 254,252 | 256,691 | 257,683 | 257,529 | 253,719 | 253,461 | - | - |
| Announcement Date | 26/1/22 | 7/2/23 | 5/2/24 | 10/2/25 | 12/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 30.42x | 8.85x | 20.01x | -.--% | 131B | |
| 34.32x | 12.47x | 25.45x | 0.57% | 1,078B | |
| 29.15x | - | - | 2.05% | 632B | |
| 32.02x | 7.45x | 15.48x | 2.73% | 443B | |
| 20.19x | 4.79x | 11.87x | 2.76% | 356B | |
| 21.62x | 5.6x | 13.97x | 2.87% | 289B | |
| 20.24x | 4.18x | 11.87x | 2.1% | 245B | |
| 26.43x | 6.88x | 12.21x | 2.41% | 226B | |
| 13.48x | 4.84x | 10.07x | 3.78% | 204B | |
| -42.9x | 6.13x | 34.58x | 2.39% | 171B | |
| Average | 18.50x | 6.80x | 17.28x | 2.17% | 377.46B | |
| Weighted average by Cap. | 24.73x | 8.22x | 18.71x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
